Product Details
BENLYSTA(BELIMUMAB 120MG)5ML
Manufacturer: Glaxo Smith Kline
MFG#: 49401-0101-01
NDC: 49401-0101-01
PID: 648349
1/EA
$ *.**
In StockAdditional Information
| Product Name | Benlysta (Belimumab 120 mg) 5 mL |
| Application | Immunosuppressive Agent |
| Generic Drug Name | Belimumab |
| Mechanism of Action | Inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells |
| Strength | 120 mg |
| Type | Intravenous |
| Volume | 5 mL |
| Route of Administration | Intravenous infusion over 1 hour |
| Dosing Frequency | Every 2 to 4 weeks, depending on condition and treatment phase |
| Common Adverse Effects | Nausea, diarrhea, headache, infusion reactions, increased infection risk |
| Premedication Required | Antihistamines and antipyretics may be needed to prevent infusion reactions |
| Container Type | Single-Use Vial |
| Storage Requirements | Requires Refrigeration (2°C to 8°C / 36°F to 46°F) |
| Indication | Systemic Lupus Erythematosus (SLE) and Lupus Nephritis |
Description
Benlysta (Belimumab 120 mg/5 mL) is a monoclonal antibody that functions as a B-lymphocyte stimulator (BLyS)-specific inhibitor. It is indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE) in patients aged 5 years and older who are receiving standard therapy. By inhibiting BLyS, belimumab reduces the survival of autoreactive B cells, thereby lowering disease activity and preventing disease flares.
Benlysta is supplied as a sterile, preservative-free, lyophilized powder for intravenous infusion. Each single-dose vial contains 120 mg of belimumab in a 5-mL volume. The formulation requires reconstitution and dilution prior to administration. The product is provided in a glass vial with a rubber stopper (not made with natural rubber latex) and a flip-off seal.
The medication is administered via intravenous infusion over one hour at intervals specified by the treatment regimen. Premedication with antihistamines and antipyretics may be required to reduce the risk of infusion-related reactions. Common adverse effects include nausea, diarrhea, infusion reactions, headache, and increased infection risk.
Frequently Asked Questions (FAQs)
The cost of BENLYSTA(BELIMUMAB 120MG)5ML is $$0.00
BENLYSTA(BELIMUMAB 120MG)5ML is manufactured by Glaxo Smith Kline.
You can purchase BENLYSTA(BELIMUMAB 120MG)5ML on our website at https://injx.pipelinemedical.com/product/detail/benlysta-pr-120mg-pf-spd-649446